Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
2.005
+0.020 (1.01%)
Oct 19, 2026, 11:08 AM EDT - Market open
Larimar Therapeutics Stock Forecast
LRMR's stock price has decreased by -52.5% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 11 analysts polled by S&P Global, Larimar Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $14.4. The average 1-year stock price forecast is 618.20% higher than the current stock price, while the lowest is $5.00 (+149.38%) and the highest is $26 (+1,196.76%).
Price Target: $14.4 (+618.20%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Larimar Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 9 | 9 | 9 | 9 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Maintains $25 | Buy | Maintains | $25 | +1,146.88% | Sep 28, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $12 → $13 | Buy | Maintains | $12 → $13 | +548.38% | Sep 14, 2026 |
| Wedbush | Wedbush | Buy Maintains $12 → $11 | Buy | Maintains | $12 → $11 | +448.63% | Aug 5, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 5, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Initiates $10 | Buy | Initiates | $10 | +398.75% | Jul 2, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
41.74M
EPS This Year
-1.35
from -2.27
EPS Next Year
-1.06
from -1.35
EPS and Forward PE are based on non-GAAP adjusted numbers.